T2 Biosystems to Report Second Quarter 2021 Financial Results on August 5, 2021
T2 Biosystems, Inc. (NASDAQ:TTOO) will report its second-quarter 2021 financial results after market close on August 5, 2021. Following the earnings release, management will host a conference call at 4:30 p.m. ET. The event can be accessed via a live and archived webcast at their website. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens and offers several diagnostic products powered by T2 Magnetic Resonance technology, aiming to enhance patient care while reducing costs.
- T2 Biosystems is a leader in rapid pathogen detection, likely supporting future revenue growth.
- None.
LEXINGTON, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the second quarter of 2021 after market close on Thursday, August 5, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 1-877-407-9208 (U.S.) or 1-201-493-6784 (International) five to ten minutes prior to the start time.
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.
Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
FAQ
When will T2 Biosystems release its second-quarter 2021 financial results?
What time is the T2 Biosystems conference call scheduled?
How can I access the T2 Biosystems conference call?
What products does T2 Biosystems offer?
What is the focus of T2 Biosystems' technology?
